Medgenics: Q3 2014 FY Results (Medgenics) - Oct 18, 2014 - Anticipated interim results from P1/2 trial for ESRD or CKD at European Society of Gene and Cell Therapy (Oct 23 - Oct 26, 2014); Anticipated completion of enrollment in MDGN-201 study in patients with anemia due to end-stage renal disease in Q4 2014; Anticipated initiation of P2 trial for beta thalassemia in H1 2015; Anticipated initiation of P2 trial in patients with anemia who are hyporespondent to EPO in Q1 2015
Anticipated enrollment status • Anticipated P1/2 data • Anticipated trial initiation date • Biosimilar
|